Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonella Castagna

Showing results (351-360 of 467) with videos related to

Pageof 47
Sort By:
AIDS Patient Care and Stds|January 10, 2023
Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical TrialTahilin Sanchez Karver, Miguel Pascual-Bernaldez, Alessandro Berni, et al.
Viruses|September 27, 2025
Virological Effectiveness of Dolutegravir Plus Darunavir in People with Multi-Drug-Resistant HIV: Data from the PRESTIGIO RegistryFilippo Lagi, Michele Bellomo, Riccardo Lolatto, et al.
Eclinicalmedicine|July 31, 2025
Risk of clinical events in virologically suppressed people with HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulationCristina Mussini, Andrea Giacomelli, Eugenia Quiros-Roldan, et al.
The Journal of Infectious Diseases|January 22, 2014
Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 studyAntonella Castagna, Franco Maggiolo, Giovanni Penco, et al.
The Lancet. HIV|November 2, 2015
Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trialJose I Bernardino, Amanda Mocroft, Patrick W Mallon, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|September 18, 2023
High-dose anakinra in addition to standard of care including corticosteroids in patients with severe COVID-19 treated with non-invasive ventilationAndrea Mastrangelo, Roberta Monardo, Laura Galli, et al.
The Journal of Antimicrobial Chemotherapy|July 15, 2024
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO RegistryDaniele Armenia, Vincenzo Spagnuolo, Maria C Bellocchi, et al.
Bone Marrow Transplantation|April 24, 2025
Risk stratification and impact of donor type on breakthrough invasive fungal infections in haematopoietic cell transplant with post-transplant cyclophosphamide and mould-active prophylaxisMatteo Chiurlo, Laura Galli, Francesca Farina, et al.
The Journal of Antimicrobial Chemotherapy|April 6, 2024
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohortAntonella d'Arminio Monforte, Alessandro Tavelli, Antonio Di Biagio, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 23, 2020
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factorsMarco Ripa, Laura Galli, Andrea Poli, et al.
Pageof 47

Showing results (351-360 of 467) with videos related to

Sort By:
Pageof 47
AIDS Patient Care and Stds|January 10, 2023
Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical TrialTahilin Sanchez Karver, Miguel Pascual-Bernaldez, Alessandro Berni, et al.
Viruses|September 27, 2025
Virological Effectiveness of Dolutegravir Plus Darunavir in People with Multi-Drug-Resistant HIV: Data from the PRESTIGIO RegistryFilippo Lagi, Michele Bellomo, Riccardo Lolatto, et al.
Eclinicalmedicine|July 31, 2025
Risk of clinical events in virologically suppressed people with HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulationCristina Mussini, Andrea Giacomelli, Eugenia Quiros-Roldan, et al.
The Journal of Infectious Diseases|January 22, 2014
Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 studyAntonella Castagna, Franco Maggiolo, Giovanni Penco, et al.
The Lancet. HIV|November 2, 2015
Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trialJose I Bernardino, Amanda Mocroft, Patrick W Mallon, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|September 18, 2023
High-dose anakinra in addition to standard of care including corticosteroids in patients with severe COVID-19 treated with non-invasive ventilationAndrea Mastrangelo, Roberta Monardo, Laura Galli, et al.
The Journal of Antimicrobial Chemotherapy|July 15, 2024
Use of next-generation sequencing on HIV-1 DNA to assess archived resistance in highly treatment-experienced people with multidrug-resistant HIV under virological control: data from the PRESTIGIO RegistryDaniele Armenia, Vincenzo Spagnuolo, Maria C Bellocchi, et al.
Bone Marrow Transplantation|April 24, 2025
Risk stratification and impact of donor type on breakthrough invasive fungal infections in haematopoietic cell transplant with post-transplant cyclophosphamide and mould-active prophylaxisMatteo Chiurlo, Laura Galli, Francesca Farina, et al.
The Journal of Antimicrobial Chemotherapy|April 6, 2024
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohortAntonella d'Arminio Monforte, Alessandro Tavelli, Antonio Di Biagio, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 23, 2020
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factorsMarco Ripa, Laura Galli, Andrea Poli, et al.
Pageof 47